Showing "Auxilium" News Articles, all 6

Auxilium Pharmaceuticals and Alimera Sciences are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability. This is a breakdown of current ratings and recommmendations for Auxilium Pharmaceuticals and Alimera Sciences, as...

Fortress Biotech and Auxilium Pharmaceuticals are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations. This is a breakdown of current ratings and price targets for Fortress Biotech and Auxilium Pharmaceuticals, as report...

NEW YORK: A federal jury in Chicago said on Thursday that Endo International's Auxilium unit was not responsible for the heart attack a man suffered while using the company's testosterone replacement drug Testim. The verdict was a victory for the drugmaker in its first trial over allegations it defectively designed Testim, a skin gel, and negligently misrepresented its risks.

BioSpecifics Technologies Corp BSTC Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies tha...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company
focused on the development and commercialization of product candidates
using its proprietary mucus-penetrating particle (MPP) technology, today
announced the appointment of Andrew I. Koven to the Company’s Board of
Directors. Mr. Koven will serve as a Class I director and serve on the
...

Completed Initial Public Offering Raising $103.5 million in gross
proceeds
Submitted New Drug Application to U.S. Food and Drug Administration
for INVELTYS™ (KPI-121 1%)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company
focused on the development and commercialization of product candidates
using its proprietary muc...